Imagine you are on your hospital bed and could not eat or drink. Every breath you take is extremely painful. How would you feel? Nasopharyngeal cancer is an orphan disease that accounts for less than one out of every 100,000 people in the US every year. It is an orphan indication and needs us to disrupt it with empathy.
Oncolux is a novel anti-cancer startup company attempting to greatly reduce the hardships caused by cancer. We are initially focusing on diminishing the effects of nasopharyngeal cancer, while making treatment more effective. Our team consists of Chinese, Indian and American students that bring a great deal of experience and ambition to Oncolux. The board of advisor consists of consulting, pharmaceuticals, postdoctoral fellows in Therapeutics and a serial entrepreneur with over 20 years experience. Our goal is to create a better and more hopeful tomorrows for cancer patients all around the globe.
The design of our technology incorporates chemotherapy and nanotechnology into one synergistic powerhouse. The chemo treatment is effective, but most patients with nasopharyngeal cancer are found too late in the metastasis for it to work as well as it could if caught in the early stages of progression. We utilize a tiny hollow capsule to safely house and deliver the chemotherapy. It has a receptor imbedded in the capsule shell that is activated by light and causes the shell to open at the precise desires spot. This allows us to deliver a stronger dose to the tumor site without adversely affecting the patient. They still have the symptoms associated with normal treatment, but this allows a more accurate and aggressive treatment regime.
By developing our platform technology specialized in treating nasopharyngeal cancer, we are expected to penetrate 25 % of the market share and gradually step into the global oncology market. We are now asking for 1 million of non-dilutive seed fund and 1.5 million dollars in Pre-A round for preclinical study to file the IND. We will also need 4 million dollars in the A round for further clinical trials. Upon completion of the phase II trial with orphan designation, we estimate to be valued 200 million dollars in 2025 with our company becoming very attractive for strategic partnership. After the Nano Startup Challenge In Cancer, we will launch the startup in New Jersey and outsource the manufacturing to CMO with Good Manufacturing Practice. The global nature of the team allows us to further go for three more major markets after the IND, namely China, Hong Kong and India. We expand with global funding and revenue from sublicensing, supported by local contract research organizations.
Throughout the Nano Startup Challenge in Cancer, we found it challenging to find a comfortable meeting time since our team is global in nature. However, we learned how to compromise with each other, and extended all of ourselves to meet twice per week in order to accommodate our team members different time zones. Difference in space and time is no longer the obstacle to us, but instead fuels us to move forward. In the public voting on YouTube, we received over 1600 likes and most comments are positive to Oncolux product. Thanks to The Center for Advancing Innovation (CAI) who organized and executed the weekly webinars to familiarize us with the biotechnology industry during this challenge. Currently we have proven in vivo assay data and we will go further for the preclinical toxicity study once we get the exclusive license from NIH. Let’s re-imagine the cancer treatment, together! -Jack Ka Wing SUNG and Patrick E. Nichols
Oncolux is a novel anti-cancer startup company attempting to greatly reduce the hardships caused by cancer. We are initially focusing on diminishing the effects of nasopharyngeal cancer, while making treatment more effective. Our team consists of Chinese, Indian and American students that bring a great deal of experience and ambition to Oncolux. The board of advisor consists of consulting, pharmaceuticals, postdoctoral fellows in Therapeutics and a serial entrepreneur with over 20 years experience. Our goal is to create a better and more hopeful tomorrows for cancer patients all around the globe.
The design of our technology incorporates chemotherapy and nanotechnology into one synergistic powerhouse. The chemo treatment is effective, but most patients with nasopharyngeal cancer are found too late in the metastasis for it to work as well as it could if caught in the early stages of progression. We utilize a tiny hollow capsule to safely house and deliver the chemotherapy. It has a receptor imbedded in the capsule shell that is activated by light and causes the shell to open at the precise desires spot. This allows us to deliver a stronger dose to the tumor site without adversely affecting the patient. They still have the symptoms associated with normal treatment, but this allows a more accurate and aggressive treatment regime.
By developing our platform technology specialized in treating nasopharyngeal cancer, we are expected to penetrate 25 % of the market share and gradually step into the global oncology market. We are now asking for 1 million of non-dilutive seed fund and 1.5 million dollars in Pre-A round for preclinical study to file the IND. We will also need 4 million dollars in the A round for further clinical trials. Upon completion of the phase II trial with orphan designation, we estimate to be valued 200 million dollars in 2025 with our company becoming very attractive for strategic partnership. After the Nano Startup Challenge In Cancer, we will launch the startup in New Jersey and outsource the manufacturing to CMO with Good Manufacturing Practice. The global nature of the team allows us to further go for three more major markets after the IND, namely China, Hong Kong and India. We expand with global funding and revenue from sublicensing, supported by local contract research organizations.
Throughout the Nano Startup Challenge in Cancer, we found it challenging to find a comfortable meeting time since our team is global in nature. However, we learned how to compromise with each other, and extended all of ourselves to meet twice per week in order to accommodate our team members different time zones. Difference in space and time is no longer the obstacle to us, but instead fuels us to move forward. In the public voting on YouTube, we received over 1600 likes and most comments are positive to Oncolux product. Thanks to The Center for Advancing Innovation (CAI) who organized and executed the weekly webinars to familiarize us with the biotechnology industry during this challenge. Currently we have proven in vivo assay data and we will go further for the preclinical toxicity study once we get the exclusive license from NIH. Let’s re-imagine the cancer treatment, together! -Jack Ka Wing SUNG and Patrick E. Nichols
RSS Feed
